Evaluating MeRT Treatment for Post-Traumatic Stress Disorder

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the safety and efficacy of Biometrics-guided Magnetic e-Resonance Therapy (MeRT) for individuals diagnosed with Post-Traumatic Stress Disorder (PTSD). The study involves a double-blind, randomized, sham-controlled design, where participants will be assigned to either active MeRT or sham treatment over a 5-week period. A total of 152 participants will be enrolled, with outcomes monitored by a Data and Safety Monitoring Board. The trial includes a pilot phase that confirmed the safety of MeRT, and participants will undergo follow-up assessments to evaluate treatment effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Participants must meet all inclusion criteria to qualify for enrollment in the study:

1. Willing and able to consent to participate in the study
2. Age 18 - 65 years
3. Diagnosis of PTSD according to DSM-V criteria via CAPS-5
4. Onset of symptoms meeting the DSM-5 criteria for PTSD symptoms persisting for a minimum of 6 months prior to the Screening Visit
5. Minimum PCL-5 score of 30

Exclusion Criteria

Participants will be excluded from study participation if one or more of the following exclusion criteria apply:

1. Index trauma occurred before the age of 16 years
2. History of open skull injury
3. History of a neurological disorder including, but not limited to:

   * Seizure disorder
   * Any condition likely to be associated with increased intracranial pressure
   * Space occupying brain lesion
4. History of cerebrovascular accident
5. History of cerebral aneurysm
6. EEG abnormalities that indicate risk of seizure, i.e., abnormal focal or general slowing, or ictal spikes, during the EEG recording
7. Inability to calculate the EEG intrinsic alpha frequency at Screening
8. Participation in any interventional research protocol within 3 months prior to the Screening Visit
9. History of any type of ECT, rTMS, or MeRT treatment
10. Treated within 30 days of the Screening Visit with any antipsychotic medication
11. Treated within 30 days of the Screening Visit with any benzodiazepine or anticonvulsant medications
12. Current treatment with any restricted concomitant medication (i.e., NDRI, SSRI, SNRI, or QBDZ) that has not been stable for the preceding 60 days at the time of the Screening Visit
13. Intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, stents, or electrodes) or any other metal object within the head, excluding the mouth, or on the head, that cannot be safely removed
14. Biomedical devices, including those not in or on the head, that are either implanted or not safe to remove, that may be affected by the magnetic field of the stimulator (e.g., cardiac pacemaker, cardioverter defibrillator (ICD), or medication dispensing device)
15. Clinically significant medical illness or condition, including, but not limited to, any uncontrolled thyroid disorders, hepatic, cardiac, pulmonary and renal malfunction, or chronic excessive alcohol consumption, that in the Investigator's judgment might pose a potential safety risk to the participant or limit the interpretation of trial results
16. Pregnant, or female unwilling to use effective birth control during the course of the trial
17. Plan to move away from the area, or knowledge that there will be an absence from the area, within 80 days following the Screening Visit (inclusive)
18. Unwilling or unable to adhere to the study treatment, data collection schedule, or study procedures, or any condition, including inability to communicate in English, which in the judgment of the Investigator might prevent the participant from completing the study, render study results uninterpretable, or represent an unacceptable safety risk to the participant or study personnel that is not otherwise listed in exclusion criteria.
19. Clinically significant psychopathology, including, but not limited to, schizophrenia or bipolar disorder, or other psychiatric disorder that in the Investigator's judgment might pose a potential safety risk to the participant, or limit the interpretation of trial results
20. An elevated risk of suicide or violence to others
21. Current psychotherapeutic treatment, expected to continue throughout the trial, that was begun in the preceding 60 days at the time of the Screening Visit

Where it's running

• BrainHealth Solutions
  Costa Mesa, California, United States Recruiting
• VA Long Beach Healthcare System
  Long Beach, California, United States Recruiting
• UNC Rex Hospital
  Raleigh, North Carolina, United States Recruiting
• Columbus Brain Research Center
  Columbus, Ohio, United States Recruiting
• Center for Interventional Pain and Spine
  Bryn Mawr, Pennsylvania, United States Recruiting
• Texas A&M Research Center
  Plano, Texas, United States Recruiting

Study contacts

• Principal investigator: Kenneth Ramos, MD,PhD — Texas A&M University
• Study coordinator: Adele Gilpin, PhD,JD
• Email: mert005b@gmail.com
• Phone: 949-229-2869

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PIONEER-Prognosis: Using biomarkers and wearables to forecast recovery after mild traumatic brain injury

  This study tests whether blood biomarkers, health data from records, and wearables can help predict how people recover after a mild traumatic brain injury treated in the emergency department.

  Recruiting at 3 sites University of Michigan · Torrance, California and 4 other locations · NCT07858266

• HBOT to see if it helps cognition and well‑being in first responders with prior brain injury

  This study tests whether 40 hyperbaric oxygen therapy sessions can improve thinking skills and post-concussion symptoms in current or former first responders with a history of brain injury.

  Recruiting Phase 2 Summit Hyperbarics and Wellness · Boise, Idaho · NCT07852728

• Depth Electrode Monitoring after Traumatic Brain Injury

  This study tests adding a depth electrode with continuous brain monitoring during external ventricular drain placement in adults with traumatic brain injury to see if cortical reverberation signals can be tracked safely.

  Recruiting Hennepin Healthcare Research Institute · Minneapolis, Minnesota · NCT07842458

• Understanding growth hormone deficiency after a brain injury in adults

  This observational study tests whether growth hormone deficiency affects quality of life and symptoms in adults with traumatic brain injury and whether GH replacement helps after 12 weeks.

  Recruiting University of Calgary · Calgary, Alberta and 1 other locations · NCT07795736

• Reboxetine plus Ritalin vs Dog-Assisted Therapy for PTSD

  This study tests whether a drug combo of reboxetine and methylphenidate works better than dog-assisted therapy for people with PTSD.

  Recruiting Phase 2 University of Haifa · Haifa · NCT07771530

• Electrical stimulation-assisted exercise for people with lower limb paralysis

  This study tests whether adding electrical stimulation during exercise can improve leg muscle strength and endurance for people with paralysis.

  Recruiting Louis Stokes VA Medical Center · Cleveland, Ohio · NCT07768761

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.